Cognoa

Cognoa operates at the intersection of pediatric behavioral health, digital diagnostics, and digital therapeutics, with autism assessment as its clearest product focus. Canvas Dx is described as a prescription system for children aged 18 to 72 months that combines caregiver input, home videos, clinician assessments, and AI-generated reports to help clinicians diagnose or rule out autism. Its stated approach brings together social, behavioral, executive-functioning, and language information, with an emphasis on equitable assessment and clinical review when results are indeterminate. The similar-company entries available for this profile resolve to Cognoa itself rather than distinct competitors, so naming specific competing companies would be unreliable. The broader competitive field includes providers of autism diagnostics and pediatric behavioral-health tools, where clinical adoption, reimbursement, access, and evidence are important constraints. Coverage in 2025 specifically highlighted payer challenges in autism diagnostics.

Cognoa’s funding history shows a long development arc, with three rounds labeled Series A in 2013, 2016, and 2019, followed by a $73.1 million Series B announced on Nov 14, 2022. The four listed rounds total $127 million, with the 2019 Series A contributing approximately $45.1 million. That financing and the Series B mark the clearest capital inflection points in the available history; no later funding date or valuation is provided. Product development is centered on Canvas Dx, a prescription digital diagnostic system for autism evaluation in children aged 18 to 72 months. Its workflow draws on caregiver responses, home video, clinician assessments, and AI-generated reports, giving the company a defined clinical product rather than only a broad platform description. The company also announced leadership expansion and strategic hires in June 2023, after Sharief Taraman became CEO in November 2022. Employee information places the organization in the 11–50 range, but does not show a time series, so hiring momentum cannot be quantified. The April 2026 collaboration announcement may indicate continued efforts to connect diagnosis with care, although details are limited.